[Tebao Bio: sign the exclusive commercialization Agreement of Tupe Fagastine injection] Science and Technology Innovation Board Daily, 31 News, Tebao Biology announcement, the company and Shanghai Fosing Pharmaceutical Industry Development Co., Ltd., a wholly-owned subsidiary of Jiangsu Fosun signed the "Tupei Fagastine injection (trade name: Liangjin ®) exclusive commercialization agreement". The company agrees to grant Jiangsu Fosun the exclusive right to promote and sell Topei Fagastine injection in Chinese mainland area, and the company can get a down payment and milestone payment of not less than 73 million yuan after the cooperative product is approved for listing, and pay the promotion service fee to Jiangsu Fosun according to the agreement. Tuopei Fagastine injection is a long-acting recombinant human granulocyte stimulating factor independently developed by the company, which is currently in the application stage of drug registration and listing.